Chester County News and Community Website
KING OF PRUSSIA, PA — SEED Therapeutics, Inc. reported new preclinical data showing anticancer activity of its RBM39 degrader candidate ST-01156 in neuroblastoma and said the drug is being evaluated …
SEED Reports Preclinical Data on RBM39 Drug in Neuroblastoma Read More KING OF PRUSSIA, PA — SEED Therapeutics, Inc. said it will present research on an RBM39 degrader targeting neuroblastoma at the 2026 American Association for Cancer Research annual meeting in …
SEED Therapeutics to Present Neuroblastoma Data at AACR Meeting Read More KING OF PRUSSIA, PA — SEED Therapeutics Inc. took a critical step from laboratory promise to human testing with the first patient dosed in a Phase 1a study of ST-01156, …
SEED’s First Human Dose Ignites a High-Stakes Bet on RNA-Targeted Cancer Drugs Read More KING OF PRUSSIA, PA — SEED Therapeutics announced that China’s National Medical Products Administration has cleared the Investigational New Drug application for ST-01156, enabling Chinese sites to participate in the …
China Clears IND for SEED Therapeutics’ First-in-Class Cancer Drug in Global Trial Push Read More KING OF PRUSSIA, PA — SEED Therapeutics, Inc. announced it has closed a $30 million Series A-3 financing and received U.S. Food and Drug Administration clearance of its Investigational New …
SEED Therapeutics Secures $30M Funding, Gains FDA Clearance for Lead Drug Read More KING OF PRUSSIA, PA — SEED Therapeutics, Inc. has been named a finalist for the 2025 Prix Galien USA “Best Start-Up” Award, a distinction often referred to as the “Nobel …
SEED Therapeutics Named Finalist for Prestigious Prix Galien USA Award Read More KING OF PRUSSIA, PA — SEED Therapeutics Inc. has announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, marking a critical addition …
SEED Therapeutics Names Dr. Bill Desmarais as CFO and CBO Read More KING OF PRUSSIA, PA — SEED Therapeutics Inc. presented compelling developments from its cancer research programs at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in …
SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 Read More KING OF PRUSSIA, PA — SEED Therapeutics Inc. has announced that its molecular glue therapy, ST-01156, has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and …
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 Read More